Top

Clinical and Translational Oncology

Published in:

01-11-2008 | Research Articles

Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer

Authors: Jesús García-Mata, Andrés García-Palomo, Lourdes Calvo, Ramón Mel, Juan Jesús Cruz, Manuel Ramos

Published in: Clinical and Translational Oncology | Issue 11/2008

Title: Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer
Authors: Jesús García-Mata
Andrés García-Palomo
Lourdes Calvo
Ramón Mel
Juan Jesús Cruz
Manuel Ramos
Publication date: 01-11-2008
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 11/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-008-0280-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 11/2008

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

FESEO and Clinical & Translational Oncology: a brief historical perspective

Granulocytic sarcoma of the right humerus in a non-leukaemia patient

Fatal pneumonitis induced by oxaliplatin

Langerhans cell histiocytosis

Adrenal metastasis of breast cancer with involvement of the inferior vena cava

Keynote webinar | Spotlight on antibody–drug conjugates in cancer